Skip to main navigation
Skip to search
Skip to main content
University of Kentucky Home
LOGIN & Help
Home
Research units
Researchers
Grants & Contracts
Research output
Facilities & Equipment
Honors & Awards
Activities
Search by expertise, name or affiliation
A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK -RDOTAP/HPV-16 E6 & E7 Peptides) and Pembrolizumab (KEYTRUDA) Combination Immunotherapy as a First Line Treatment in Subjects with Recurrent
Zinner, Ralph
(PI)
Kejner, Alexandra
(Former PI)
Markey Cancer Center / Cancer Research Priority Initiative
Overview
Grants and Contracts Details
Status
Active
Effective start/end date
11/2/20
→
7/26/24
Funding
PDS Biotechnology:
$136,581.00
View all
View less